Camurus AB (CAMX) AI Stock Analysis

• Market Cap: kr37.35B
• Dividend Yield: N/A
• Average Volume (3M): 84.55K
• Price to Earnings (P/E): 51.2
• Beta (1Y): 0.72
• Revenue Growth: 42.25%
• EPS Growth: 210.72%
• Country: SE
• Employees: 238
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 4.08
• Shares Outstanding: 59,848,633
• 10 Day Avg. Volume: 68,526
• 30 Day Avg. Volume: 84,546
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: kr718.00 ▲(7.89% Upside)

Camurus AB's strong financial performance is the primary driver of its stock score, supported by robust revenue growth and profitability. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.

Camurus AB Business Overview & Revenue Model

Company Description

Camurus AB (CAMX) is a Swedish biotechnology company focused on developing and commercializing innovative drug delivery technologies and products for the treatment of various severe and chronic diseases, particularly in the fields of pain management and addiction. The company leverages its proprietary FluidCrystal® technology platform to create long-acting injectable formulations, enhancing patient adherence and improving therapeutic outcomes. Camurus' core products include Buvidal, an injectable formulation for the treatment of opioid dependence, and other pipeline candidates targeting different therapeutic areas.

How the Company Makes Money

Camurus AB generates revenue primarily through the commercialization of its products, including Buvidal, which is sold in various international markets. The company earns revenue from product sales, licensing agreements, and collaborations with pharmaceutical partners for the development and distribution of its drug formulations. Key revenue streams include royalties and milestones from partnerships, as well as direct sales from its proprietary drugs. Camurus has established significant partnerships with larger pharmaceutical companies, which provide not only financial support but also facilitate market access and distribution, thereby enhancing its earnings potential.

Camurus AB Financial Statement Overview

Summary

Camurus AB demonstrates strong financial health with robust revenue growth, high profitability, and efficient cash flow management. The company's low leverage and high return on equity further underscore its financial stability and operational efficiency. These strengths position Camurus AB well for future growth and resilience in the biotechnology industry.

Income Statement

Camurus AB has demonstrated strong revenue growth with a TTM revenue growth rate of 11.33%. The company maintains high profitability with a gross profit margin of 93.50% and a net profit margin of 31.69% in the TTM. The EBIT and EBITDA margins are also robust at 40.40% and 41.25%, respectively, indicating efficient operations. These metrics highlight the company's strong market position and operational efficiency.

Balance Sheet

The company exhibits a solid financial structure with a low debt-to-equity ratio of 0.027, suggesting minimal leverage and financial risk. The return on equity is healthy at 20.88%, reflecting effective use of equity to generate profits. The equity ratio stands at 87.50%, indicating a strong equity base relative to total assets, which enhances financial stability.

Cash Flow

Camurus AB shows impressive cash flow performance with a significant free cash flow growth rate of 68.47% in the TTM. The operating cash flow to net income ratio of 1.53 indicates strong cash generation relative to net income. The free cash flow to net income ratio of 0.88 further supports the company's ability to convert earnings into cash, which is crucial for sustaining operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.27B	1.87B	1.72B	956.34M	600.57M	336.00M
Gross Profit	2.12B	1.74B	1.59B	853.08M	515.22M	300.71M
EBITDA	934.93M	568.24M	562.54M	87.59M	-97.72M	-196.58M
Net Income	718.37M	428.39M	431.44M	55.55M	-90.45M	-167.26M
Balance Sheet
Total Assets	4.42B	3.76B	1.91B	1.31B	1.08B	1.04B
Cash, Cash Equivalents and Short-Term Investments	3.35B	2.85B	1.19B	565.54M	411.57M	461.79M
Total Debt	103.80M	17.04M	24.51M	26.22M	25.66M	25.48M
Total Liabilities	553.52M	467.33M	414.82M	310.82M	232.99M	196.66M
Stockholders Equity	3.87B	3.29B	1.49B	994.67M	848.91M	847.44M
Cash Flow
Free Cash Flow	618.96M	358.62M	596.75M	99.29M	-148.37M	-242.16M
Operating Cash Flow	706.33M	387.99M	606.88M	101.20M	-143.43M	-238.83M
Investing Cash Flow	-87.37M	-29.37M	-10.13M	5.38M	-4.94M	-3.33M
Financing Cash Flow	173.77M	1.30B	28.76M	43.70M	98.90M	347.85M

Camurus AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 665.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CAMX, the sentiment is Negative. The current price of 665.5 is below the 20-day moving average (MA) of 670.63, below the 50-day MA of 690.54, and above the 200-day MA of 631.32, indicating a bearish trend. The MACD of -14.33 indicates Positive momentum. The RSI at 28.16 is Positive, neither overbought nor oversold. The STOCH value of 14.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CAMX.

Camurus AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOA.B	―	kr25.79B	24.13	72.22%	―	521.22%	―
CAMX	―	kr37.35B	51.17	20.47%	―	42.25%	210.72%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XSPRAY	―	€1.09B	―	-41.54%	―	―	0.57%
VICO	―	kr2.62B	―	-55.23%	―	-92.57%	-7.72%
HNSA	―	kr3.33B	-3.77	―	―	20.12%	40.54%
BINV	―	$1.83B	-6.27	-28.70%	―	382.81%	23.87%

Camurus AB Corporate Events

Camurus Increases Shares and Votes Following Employee Stock Option Exercise

Camurus has announced an increase in its number of shares and votes following the exercise of 188,050 employee stock options from its ESOP 2022/2026 program. This change reflects the company’s ongoing commitment to employee participation and could impact its market positioning by potentially enhancing shareholder value.

The most recent analyst rating on (SE:CAMX) stock is a Hold with a SEK697.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.